Lexaria Bioscience' Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension

  • Lexaria Bioscience Corp LEXX has received a positive full written response from the FDA from its pre-Investigational New Drug (Pre-IND) meeting regarding DehydraTECH-CBD for hypertension.
  • The FDA confirmed that it agreed with Lexaria's proposal to pursue a 505(b)(2) new drug application regulatory pathway for its program.
  • The pathway is advantageous because this abbreviated pathway, as it is often described, typically enables a faster route to commercial approval than the traditional 505(b)(1) pathway.
  • Also Read: Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs.
  • Lexaria's proposed Phase 1b clinical protocol for DehydraTECH-CBD for hypertension in 100 patients received favorably by the FDA to open the IND application to allow Lexaria to work towards full registration of DehydraTECH-CBD for hypertension.
  • The agency also said that additional non-clinical studies are not required before initiating the DehydraTECH-CBD IND program.
  • Lexaria remains on track to file its full IND application with the FDA by late 2022 / early 2023. 
  • Price Action: LEXX shares are down 2.15% at $2.73 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!